GlobeNewswire

Symphony Talent Continues Growth, Adds New Clients

Dela

Brands across all industries tap into Symphony Talent's innovative talent acquisition solutions

 

New York, May 01, 2018 (GLOBE NEWSWIRE) -- Symphony Talent, a leading Talent Acquisition solutions provider, today announced additions to its global client base across a diversified field of industries, demonstrating the company's continued momentum in applying its data-driven, consumer marketing approach in the HR tech and Employer Branding space through the company's Hodes, M-Cloud and X-Cloud solutions.

"Today's Talent Acquisition leaders are not only expected to attract, hire and engage the best talent but also to help drive the change management agenda in their organization's transformation," said Roopesh Nair, president and CEO, Symphony Talent.  "Our strong growth trajectory is indicative of a global trend as organizations continue to recognize the need to leverage data while bringing digital and brand to the core of their operations to meet the changing expectations of the social, mobile and digital natives who are their customers, candidates and employees."

Symphony Talent's fully modular solutions (Hodes, M-Cloud and X-Cloud) go far beyond just what recruiters and candidates need, to provide what they expect in today's consumer-centric environment.  By combining employer branding, recruitment marketing, award winning creative, candidate and employee engagement, and media optimization, Symphony Talent's solutions empower leading brands to redefine and modernize their talent acquisition and employee engagement efforts. The result is the delivery of personalized, relevant and captivating experiences for recruiters, candidates and employees.

The company recently added more than 20 new marquee brands to its global portfolio. These signings, the organization's expanded relationships with existing clients, and the continued solutions innovation are key drivers of Symphony Talent's successful start in 2018.  Recent client additions across North America, Europe and APAC include: Bashas' Inc., Invesco, Fidelity National Information Services (FIS), Highmark Health, Compass Group Canada, Liberty Mutual, VCA, Parsons, Cambridge Consultants, Baylor, Scott & White, Regis Corporation,  UCLA Health, Sonova, Orkla, Merck, Sky and Epsilon.

European Managing Director, Simon Phillips added; "It's been a hugely exciting time over the past 12-months watching our rapid growth evolve even further with the combination of award-winning creative and brand strategy being powered by game-changing technology. This is delivering incredible personalized experiences both inside and outside of the organizations we're working with and for the new clients we're winning."

"Organizations in APAC are increasingly differentiating themselves through investments in technology and award winning creative," noted Kesavan Kanchi Kandadai, Managing Director for India and APAC. "Symphony Talent recognizes that need and is excited to help organizations realize their brand promise through the power of our innovative solutions. These recent client additions serve to strengthen our commitment to invest and grow our Asia Pacific business in the next 2 years."

"Our customers are realizing significant, measurable results as they leverage our solutions to attract, hire, and engage the highest quality talent," Nair added. "I'm proud of the trust our clients invest with us, as well as our global team's commitment to innovation to ensure that our solutions are evolving with our client's and the market's needs."


About Symphony Talent

Symphony Talent is redefining how employers and talent connect. By applying data-driven consumer marketing best practices, we provide seamless, personalized experiences through our best-in-class smart technology, award winning creative, and trusted strategy and client services solutions. We simplify and streamline the process to find, hire, and engage talent. The result is a unified, seamless experience for recruiters, hiring managers, and candidates.  Companies such as Northwell Health, Chili's and UnitedHealth Group rely on Symphony Talent to power their talent acquisition efforts. For more information, visit: www.symphonytalent.com or follow us on Twitter, @SymphonyTalent_.

 

 

 

# # #

 

Colleen Naugle
Symphony Talent
4844592686
colleen.naugle@symphonytalent.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Symphony Talent via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum